• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Further discovery of caffeic acid derivatives as novel influenza neuraminidase inhibitors

tetano

Editor, Senior Moderator
Bioorg Med Chem. 2013 Oct 26. pii: S0968-0896(13)00885-7. doi: 10.1016/j.bmc.2013.10.020. [Epub ahead of print]
Further discovery of caffeic acid derivatives as novel influenza neuraminidase inhibitors.
Xie Y, Huang B, Yu K, Xu W.
Source

Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University, 44, West Culture Road, Jinan, Shandong 250012, PR China. Electronic address: yuanchaox623@aliyun.com.
Abstract

Eight series of compounds, each series containing two to five compounds were prepared by structural modifications of a lead, which was previously discovered as a mild influenza neuraminidase (NA) inhibitor. On the basis of the biological result, a detailed structure-activity relationship (SAR) was derived and discussed. Several caffeic acid derivatives that acted as non-competitive inhibitors were close or superior to the lead and also presented good antiviral activities in cells. Besides, it was interesting to find that modifications of the lead with different strategies could result in selective inhibition against N1 or N2. The preliminary docking analysis indicated that the 150-cavity of the enzymes played an important role in the selective inhibition.

Copyright ? 2013 Elsevier Ltd. All rights reserved.
KEYWORDS:

Caffeic acid, Influenza, Inhibitor, Neuraminidase

PMID:
24262883
[PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/24262883
 
Back
Top Bottom